secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001193125-25-047882
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ
-------------------------------------------------------------------

- FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).
- Over 300,000 filled prescriptions launch-to-date, up ~110% since last earnings report.
- Q4 net loss $74.5M; non-GAAP adjusted net loss $56.4M vs $46.0M in prior year Q4.
- SG&A expenses rose to $290.7M in FY2024 vs $117.9M in FY2023 due to commercial buildout.
- Phase 2 EoE trial for VOQUEZNA to begin enrollment in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/0001193125-25-047882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/d940367d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-047882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer